Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Notes Payables (2020 - 2021)

Cyclerion Therapeutics has reported Notes Payables over the past 2 years, most recently at $3.5 million for Q3 2021.

  • Quarterly results put Notes Payables at $3.5 million for Q3 2021, changed 0.0% from a year ago — trailing twelve months through Sep 2021 was $3.5 million (changed 0.0% YoY), and the annual figure for FY2020 was $3.5 million, changed.
  • Notes Payables for Q3 2021 was $3.5 million at Cyclerion Therapeutics, roughly flat from $3.5 million in the prior quarter.
  • Over the last five years, Notes Payables for CYCN hit a ceiling of $3.5 million in Q2 2020 and a floor of $3.5 million in Q2 2020.